Immunome, Inc. (IMNM)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Immunome, Inc. (IMNM)
Company Performance

Current Price

as of Oct 16, 2024

$12.34

P/E Ratio

N/A

Market Cap

$741.07M

Description

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Metrics

Overview

  • HQBothell, WA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerIMNM
  • Price$12.34+1.31%

Trading Information

  • Market Cap$741.07M
  • Float81.58%
  • Average Daily Volume (1m)809,302
  • Average Daily Volume (3m)648,620
  • EPS-$7.69

Company

  • Revenue$10.78M
  • Rev Growth (1yr)-44.55%
  • Net Income-$36.12M
  • Gross Margin71.53%
  • EBITDA Margin-1,663.96%
  • EBITDA-$39.34M
  • EV$449.65M
  • EV/Revenue41.70
  • P/EN/A
  • P/S68.58
  • P/B2.92
Documents
SEC Filings
8-K (2024-10-08)
8-K (2024-08-12)
8-K (2024-06-13)
8-K (2024-05-14)
8-K (2024-04-30)
8-K (2024-04-25)
8-K (2024-03-28)
8-K (2024-03-26)
8-K (2024-02-14)
8-K (2024-02-13)
8-K (2024-02-06)
8-K (2024-02-01)
8-K (2024-01-11)
8-K (2024-01-08)
8-K (2024-01-02)
8-K (2023-12-29)
8-K (2023-12-26)
8-K (2023-11-15)
8-K (2023-11-09)
8-K (2023-11-08)
8-K (2023-10-04)
8-K (2023-09-21)
8-K (2023-08-09)
8-K (2023-07-05)
8-K (2023-06-29)
8-K (2023-06-13)
8-K (2023-05-05)
8-K (2023-03-16)
8-K (2023-01-30)
8-K (2023-01-06)
10-Q (2024-08-12)
10-Q (2024-05-14)
10-Q (2023-11-09)
10-Q (2023-08-09)
10-Q (2023-05-05)
10-K (2024-03-28)
10-K (2023-03-16)
Factset
Factset Business Description
Factset Street Account
Immunome reports Q3 EPS ($0.36) vs year-ago ($0.75) ($8.80, 0.00) (2023-11-09T13:10:27Z)
Immunome initiated outperform at Wedbush Securities ($7.75, 0.00) (2023-12-19T12:56:00Z)
Immunome holder Enavate Sciences discloses 8.1% stake - 13D ($8.38, 0.00) (2023-10-12T20:42:56Z)
Immunome and Morphimmune announce completion of previously announced merger ($8.20, 0.00) (2023-10-03T12:09:08Z)